[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 18, 2000

Problems in Pharmacoeconomic Analyses—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(15):1922-1924. doi:10.1001/jama.284.15.1921

To the Editor: The experience of the Comitato Inter-Ministeriale Programmazione Economica (CIPE) of the Italian Ministry of Health (the body responsible for national drug reimbursement negotiations) is similar to that of Dr Hill and colleagues.1 From January 1999 to April 2000, we reviewed 212 applications by the pharmaceutical industry, of which fewer than 10% included a pharmacoeconomic analysis. We identified 2 consistent aspects of inadequate pharmacoeconomic methodology.

First Page Preview View Large
First page PDF preview
First page PDF preview
×